Research Topics
Genomes and GenesSpecies | Christie BallantyneSummaryAffiliation: Baylor College of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reductionChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Texas, USA
Am J Cardiol 96:14K-19K; discussion 34K-35K. 2005..Clinical trials are needed to determine which treatment strategies provide optimal cardiovascular risk reduction...
LDL-C goal attainment with ezetimibe plus simvastatin coadministration vs atorvastatin or simvastatin monotherapy in patients at high risk of CHDJames McKenney
National Clinic Research, Inc, Richmond, Virginia, USA
MedGenMed 7:3. 2005....
Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemiaChristie Ballantyne
Section of Atherosclerosis, Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, 6565 Fannin, MS A601, Houston, TX 77030, USA
J Clin Lipidol 6:235-43. 2012..The use of extended-release niacin and the prostaglandin D₂ receptor antagonist laropiprant (ERN/LRPT) reduces niacin-induced flushing in patients while preserving its lipid-modifying effects...- Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)Christie M Ballantyne
Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
Am J Cardiol 110:984-92. 2012.... - Racial differences in association of elevated interleukin-18 levels with type 2 diabetes: the Atherosclerosis Risk in Communities studySmita I Negi
Section of Cardiovascular Research, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, TX, USA
Diabetes Care 35:1513-8. 2012..However, so far this association has been shown only in predominantly white populations. We examined IL-18 levels and their association with incident DM in a racially heterogeneous population... - Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging studyChristie M Ballantyne
Baylor College of Medicine, and Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
Am Heart J 163:515-21, 521.e1-3. 2012..This study analyzed the effect of dalcetrapib on lipoprotein profile, CETP activity, and cellular cholesterol efflux when co-administered with pravastatin in patients with low or average HDL-C... - Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosisSuet Nee Chen
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center and Texas Heart Institute, Houston, TX, USA
BMC Med Genet 10:111. 2009.... - The transcription factor 7-like 2 (TCF7L2) polymorphism may be associated with focal arteriolar narrowing in Caucasians with hypertension or without diabetes: the ARIC StudyYu Yan
Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA
BMC Endocr Disord 10:9. 2010..We therefore aimed to investigate the association between the transcription factor 7-like 2 (TCF7L2) rs7903146 polymorphism and retinal microvascular phenotypes in the Atherosclerosis Risk in Communities (ARIC) Study (1993-1995)... - The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosisSuet Nee Chen
Center for Cardiovascular Genetics, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center, and Texas Heart Institute, Houston, TX 77030, USA
BMC Cardiovasc Disord 9:3. 2009..The LCAS is a randomized placebo-control longitudinal follow-up study in patients with CAD conducted to test the effects of fluvastatin on progression or regression of coronary atherosclerosis... - Role of selective cholesterol absorption inhibition in the management of dyslipidemiaChristie M Ballantyne
Department of Medicine, Baylor College of Medicine, 6565 Fannin Street, MS A 601, Suite A656B, Houston, TX 77030, USA
Curr Atheroscler Rep 6:52-9. 2004..Ezetimibe is an effective treatment option that may enable more patients with hypercholesterolemia to achieve optimal cholesterol levels and reduce their risk for coronary heart disease... - Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burdenChristie M Ballantyne
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, Tex 77030, USA
Circulation 117:2458-66. 2008..Intravascular ultrasound showed atheroma volume regression in a single coronary artery with <50% angiographic luminal narrowing... - Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: results of the Comparative HDL Efficacy and Safety Study (CHESS)Christie M Ballantyne
Baylor College of Medicine, Houston, Tex 77030, USA
Am Heart J 146:862-9. 2003..Previous studies have shown that effects on high-density lipoprotein cholesterol (HDL-C) may differ among statins... - Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factorsChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cornerstone 8:S6-13. 2007..Weight loss has also been shown to improve risk factors associated with metabolic syndrome... - Fluvastatin reduces cardiac mortality in patients with coronary heart diseaseChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas 77030, USA
Cardiovasc Drugs Ther 18:67-75. 2004..To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD)... - Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) studyChristie M Ballantyne
Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Methodist DeBakey Heart Center, Houston, Tex 77030, USA
Circulation 109:837-42. 2004..Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a proinflammatory enzyme associated primarily with LDL... - Metabolic syndrome risk for cardiovascular disease and diabetes in the ARIC studyC M Ballantyne
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Int J Obes (Lond) 32:S21-4. 2008..Several analyses from the Atherosclerosis Risk in Communities (ARIC) study have been performed to examine the role of the metabolic syndrome and its components in predicting risk for cardiovascular disease and diabetes... - Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trialChristie M Ballantyne
Methodist DeBakey Heart Center, Houston, Texas, USA
Clin Ther 26:1855-64. 2004..Patients with severe hypercholesterolemia may need greater cholesterol reductions than can be achieved with statin therapy alone... - Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study)Christie M Ballantyne
Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA
Am J Cardiol 101:1428-36. 2008..In conclusion, this study showed that NER/S provided additional clinically relevant improvements in multiple lipid parameters and was safe and well tolerated... - Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemiaC M Ballantyne
Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, TX 77030, USA
Int J Clin Pract 58:653-8. 2004..More EZE + ATV patients achieved LDL-C goal than ATV patients at study endpoint (91 vs. 78%, respectively; p = 0.02). Thus, the coadministration of EZE + ATV for 12 months was well tolerated and more efficacious than ATV monotherapy... - Markers of inflammation and their clinical significanceChristie M Ballantyne
Section of Atherosclerosis and Lipoprotein Research, Baylor College of Medicine, 6565 Fannin, M S A 601, Houston, TX 77030 3498, USA
Atheroscler Suppl 6:21-9. 2005.... - Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk in Communities (ARIC) studyVijay Nambi
Department of Medicine, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Stroke 40:376-81. 2009.... - Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reductionChristie M Ballantyne
aBaylor College of Medicine and the Methodist DeBakey Heart Center, Houston, Tex 77030, USA
Am Heart J 148:S3-8. 2004..More effective lipid-lowering therapy than that currently practiced may be needed in many patients to achieve optimal CHD risk reduction... - Strategies for optimizing lipid managementChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX 77030, USA
Postgrad Med 116:13-20. 2004..Identification of optimal lipid targets and increased efforts to achieve those targets may help reduce the cardiovascular risk that remains despite lipid-lowering therapy that is currently considered adequate or even aggressive... - Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) studyChristie M Ballantyne
Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Houston, Tex 77030, USA
Arch Intern Med 165:2479-84. 2005..We assessed Lp-PLA2 and C-reactive protein (CRP) levels along with traditional risk factors to examine their relation to ischemic stroke... - Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the Heart Protection Study on standards of efficacy and safetyChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 92:3K-9K. 2003..New statins, such as rosuvastatin, offer the prospect of improved lipid-lowering therapy... - Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) IIChristie M Ballantyne
Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, TX, USA
Am Heart J 151:975.e1-9. 2006..This target can be difficult to attain with diet and current therapy... - Newer risk markers and surrogate endpoints in atherosclerosis managementC M Ballantyne
Atherosclerosis Section, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cardiol 24:III13-7. 2001.... - Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levelsC M Ballantyne
Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 88:265-9. 2001.... - Treating mixed dyslipidemias: why and howC M Ballantyne
Section of Atherosclerosis, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cardiol 24:II-6-9. 2001..Combination therapy with a statin plus either a fibrate or niacin is effective in improving the entire lipid profile, but may increase cost and side effects... - Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysisC M Ballantyne
Baylor College of Medicine, Houston, Texas 77030, USA
Clin Ther 23:177-92. 2001..Fluvastatin delivery to the liver in a slower but sustained fashion would be expected to avoid hepatic saturation without elevating systemic drug levels... - Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapyC M Ballantyne
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
J Am Coll Cardiol 36:1572-8. 2000.... - Efficacy and safety of an extended-release formulation of fluvastatin for once-daily treatment of primary hypercholesterolemiaC M Ballantyne
Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 86:759-63. 2000..Fluvastatin ER was well tolerated. Thus, the new ER formulation of fluvastatin was effective and well tolerated in the once-daily treatment of primary hypercholesterolemia... - Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapyC M Ballantyne
Baylor College of Medicine, Houston, Tex 77030, USA
Circulation 99:736-43. 1999..CONCLUSIONS--Although the predominant lipid-modifying effect of fluvastatin is to decrease LDL-C, patients with low HDL-C received the greatest angiographic and clinical benefit... - Cholesterol, lipids, and statinsChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Texas, USA
Tex Heart Inst J 32:378-9. 2005..An exciting area for potentially even greater reduction in events is raising HDL-C in conjunction with aggressive efforts to lower LDL-C... - Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)Christie M Ballantyne
Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA
Am J Cardiol 99:673-80. 2007..In conclusion, rosuvastatin plus ezetimibe may improve the management of high-risk patients who cannot achieve goal on maximal statin monotherapy... - Role of lipid and lipoprotein profiles in risk assessment and therapyChristie M Ballantyne
Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
Am Heart J 146:227-33. 2003..Therapies with beneficial effects across the lipid profile would be expected to improve CHD risk reduction... - Increasing prevalence of obesity and clustered cardiometabolic risk: can treatment of the underlying cause reverse the trends?Christie M Ballantyne
Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Crit Pathw Cardiol 6:41-5. 2007..More effective management of patients with metabolic syndrome to prevent diabetes and cardiovascular disease will require more effective therapies that target the underlying cause... - Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglyceridesChristie M Ballantyne
Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, Houston, TX 77030, USA
Cardiovasc Drugs Ther 25:59-67. 2011..The objective of this study was to evaluate the long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients at goal for low-density lipoprotein cholesterol (LDL-C) but with persistent hypertriglyceridemia... - Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trialChristie M Ballantyne
Baylor College of Medicine, 6565 Fannin Street, MS A 601, Houston, Tex 77030, USA
Circulation 107:2409-15. 2003..Contributing factors may be inadequate dosing, increased risk for adverse effects with high-dose monotherapy, and increased potential for intolerance and adverse effects with combinations of available agents... - Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). cmb@bcm.tmc.eduChristie M Ballantyne
Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX 70030, USA
J Clin Lipidol 5:401-7. 2011..Combination therapy with a statin and a fibrate may be more effective than statin monotherapy for reducing hsCRP, especially in patients with mixed dyslipidemia... - Efficacy of rosuvastatin 10 mg in patients with the metabolic syndromeChristie M Ballantyne
Methodist DeBakey Heart Center and Baylor College of Medicine, Houston, Texas, USA
Am J Cardiol 91:25C-27C; discussion 28C. 2003..Among patients who met the metabolic syndrome criteria and who had triglycerides > or =200 mg/dL, 64% met their ATP III non-HDL goals... - Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) StudySalim S Virani
Michael E DeBakey Veterans Affairs Medical Center Health Services Research and Development Center of Excellence, Houston, TX, USA
Circulation 125:241-9. 2012..We evaluated associations between Lp(a) and incident CVD events in blacks and whites in the Atherosclerosis Risk in Communities (ARIC) study... - Risk for myopathy with statin therapy in high-risk patientsChristie M Ballantyne
Center for Cardiovascular Disease Prevention, Baylor College of Medicine, 6565 Fannin, Mail Station A601, Suite A656, Houston, TX 77030, USA
Arch Intern Med 163:553-64. 2003..Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease... - Effects of lipid lowering therapy on progression of coronary and carotid artery diseaseC M Ballantyne
Baylor College of Medicine, Houston, Texas 77030, USA
Curr Opin Lipidol 8:354-61. 1997..Angiographic and arterial ultrasound trials of lipid lowering therapy have demonstrated benefits on disease progression that are consistent with benefits on myocardial infarction, stroke, and death reported in larger, lengthier trials... - From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part IIMorteza Naghavi
The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
Circulation 108:1772-8. 2003..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients... - A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosisSuet N Chen
Section of Cardiology, Center for Preventive Cardiology, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
J Am Coll Cardiol 45:1611-9. 2005.... - P-selectin Thr715Pro polymorphism predicts P-selectin levels but not risk of incident coronary heart disease or ischemic stroke in a cohort of 14595 participants: the Atherosclerosis Risk in Communities StudyKelly A Volcik
Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030, USA
Atherosclerosis 186:74-9. 2006.... - Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the MERCURY II (Measuring Effective Reductions in Cholesterol Using RosuvasChristie M Ballantyne
Baylor College of Medicine and the Methodist DeBakey Heart and Vascular Center, Houston, Texas 77030, USA
J Am Coll Cardiol 52:626-32. 2008..The purpose of this analysis was to compare concentrations of low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B (apoB) before and during statin therapy... - Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemiaChristie M Ballantyne
Baylor College of Medicine, Houston, Texas, USA
Am J Cardiol 93:1487-94. 2004..5%; p <0.001). All treatments were well tolerated. Thus, a greater LDL cholesterol decrease and HDL cholesterol increase were attained by treating patients with co-administration of ezetimibe and simvastatin than with atorvastatin... - Combination therapy for combined dyslipidemiaAntonios M Xydakis
Division of Endocrinology and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 90:21K-29K. 2002..Clinical trials are needed to determine the optimal treatment in patients with combined dyslipidemia... - Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatinLorraine Salek
Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
J Mol Med (Berl) 80:737-44. 2002..There were no significant interactions between SCAP genotypes and response to therapy. Thus we detected a strong graded interaction between SREBF-1a -36del/G genotypes and response of plasma apoA-I to treatment with fluvastatin... - Genetic determinants of plasma von Willebrand factor antigen levels: a target gene SNP and haplotype analysis of ARIC cohortMarco Campos
Section of Cardiology, Baylor College of Medicine, Houston, TX, USA
Blood 117:5224-30. 2011..In summary, we identified a cluster of intronic VWF SNPs that associate with plasma levels of VWF, individually or additively, in a large cohort of healthy subjects... - Tracking regression and progression of atherosclerosis in human carotid arteries using high-resolution magnetic resonance imagingGareth J Adams
Structural and Computational Biology and Molecular Biophysics Program, Baylor College of Medicine, Houston, TX, USA
Magn Reson Imaging 22:1249-58. 2004..MRI tracking of changes in atherosclerotic plaques should prove useful in assessing vascular disease risk and monitoring the efficacy of interventions designed to induce regression or retard progression... - Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis studySuetnee Chen
Sections of Cardiology and Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Pharmacogenetics 14:61-71. 2004..PPARD and PPARG haplotypes are independent determinants of plasma levels of lipids, severity of coronary atherosclerosis and its response to therapy... - Biological surrogates for enhancing cardiovascular risk prediction in type 2 diabetes mellitusLaDale St Clair
Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Am J Cardiol 99:80B-88B. 2007.... - LPL polymorphism predicts stroke risk in menAlanna C Morrison
Human Genetics Center, University of Texas Houston Health Science Center, Houston, Texas 77030, USA
Genet Epidemiol 22:233-42. 2002..This association does not appear to be mediated by triglyceride, high-density lipoprotein (HDL)- and low-density lipoprotein (LDL)-cholesterol levels, or additional stroke risk factors... - Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participantsKelly A Volcik
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
Am J Epidemiol 164:342-8. 2006..The ApoE epsilon2 and epsilon4 alleles were associated with carotid IMT measures in both racial groups, but, after adjusting for lipid parameters, only the epsilon4 allele was associated with carotid IMT measures in African Americans... - APOE/C1/C4/C2 hepatic control region polymorphism influences plasma apoE and LDL cholesterol levelsKathy Klos
Human Genetic Center, University of Texas Health Science Center at Houston, Houston, TX 77225, USA
Hum Mol Genet 17:2039-46. 2008.... - Lipids and CVD management: towards a global consensusChristie Ballantyne
Arteriosclerosis and Lipoprotein Section, Baylor College of Medicine, Houston, TX, USA
Eur Heart J 26:2224-31. 2005..It also highlights areas where the guidelines differ and discusses points to consider when selecting the most appropriate recommendation... - Association of circulating matrix metalloproteinases with carotid artery characteristics: the Atherosclerosis Risk in Communities Carotid MRI StudyJohn W Gaubatz
Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, TX 77030, USA
Arterioscler Thromb Vasc Biol 30:1034-42. 2010.... - CD11c expression in adipose tissue and blood and its role in diet-induced obesityHuaizhu Wu
Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine, Houston, Tex 77030, USA
Arterioscler Thromb Vasc Biol 30:186-92. 2010..To examine CD11c, a beta(2)-integrin, on adipose tissue (AT) leukocytes and blood monocytes and its role in diet-induced obesity... - Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitusAbu R Vasudevan
Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cornerstone 7:7-16. 2005.... - Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) studyChristie M Ballantyne
Department of Medicine, Baylor College of Medicine, Houston, Tex, USA
Am Heart J 149:464-73. 2005..Ezetimibe/simvastatin is a highly efficacious, well-tolerated treatment option for hypercholesterolemic patients... - Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 systemMine Y Liu
Section of Atherosclerosis, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Clin Chem 51:1102-9. 2005.... - Peripheral arterial occlusive disease: magnetic resonance imaging and the role of aggressive medical managementAlan B Lumsden
Methodist DeBakey Heart Center, Baylor College of Medicine, 1709 Dryden Street, Suite 1500, Houston, Texas 77030, USA
World J Surg 31:695-704. 2007..These studies will advance our understanding of the molecular mechanisms of inflammation and thrombosis associated with aggressive lipid modification... - Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restrictionAntonios M Xydakis
Division of Endocrinology, Diabetes and Metabolism, Baylor College of Medicine, Houston, Texas 77030, USA
J Clin Endocrinol Metab 89:2697-703. 2004..Thus, increases in plasma levels of adiponectin or reductions in TNF-alpha are not required for marked improvements in glucose/insulin and lipid metabolism with acute weight loss... - Utility of statin therapy using high-sensitivity C-reactive protein as an indicator of coronary heart disease riskVijay Nambi
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Curr Atheroscler Rep 7:22-8. 2005..The utility of CRP as a target of therapy remains to be proved, and these ongoing studies will likely provide us with guidance... - Role of biomarkers in developing new therapies for vascular diseaseVijay Nambi
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center, 6565 Fannin, M S A 601, Houston, Texas 77030, USA
World J Surg 31:676-81. 2007..These biomarkers may be used to identify specific populations that may benefit from therapies, as surrogate markers of clinical efficacy, or as targets of therapy... - Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities StudyShun Kohsaka
Texas Heart Institute, Baylor College of Medicine, Houston, TX, United States
Atherosclerosis 196:926-30. 2008..The present study explored whether the COX-2 G-765C polymorphism contributes to increased incidence of coronary heart disease (CHD) or stroke in the large prospective Atherosclerosis Risk in Communities (ARIC) Study... - Impact of adding a single allele in the 9p21 locus to traditional risk factors on reclassification of coronary heart disease risk and implications for lipid-modifying therapy in the Atherosclerosis Risk in Communities studyAriel Brautbar
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA
Circ Cardiovasc Genet 2:279-85. 2009.... - Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolismKe Ma
Section of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine and Methodist Hospital, Houston, TX 77030, USA
Proc Natl Acad Sci U S A 100:2748-53. 2003..We conclude that EL is a major determinant of HDL concentration, structure, and metabolism in mice, and a major determinant of HDL concentration in humans... - Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) StudySalman Waheed
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Am J Kidney Dis 60:207-16. 2012.... - Peroxisome proliferator-activated receptor [alpha] genetic variation interacts with n-6 and long-chain n-3 fatty acid intake to affect total cholesterol and LDL-cholesterol concentrations in the Atherosclerosis Risk in Communities StudyKelly A Volcik
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
Am J Clin Nutr 87:1926-31. 2008..The binding of polyunsaturated fatty acids (PUFAs) to PPARA results in rapid changes in the expression of genes involved in lipid oxidation, with long-chain n-3 fatty acids being potent activators of PPARA... - ASCOT-LLA and the primary prevention of coronary artery disease in hypertensive patientsVijay Nambi
Department of Medicine, Baylor College of Medicine, 6565 Fannin, MS A-601, Houston, TX 77030, USA
Curr Atheroscler Rep 6:353-8. 2004..These results suggest that all hypertensive patients with additional risk factors should receive lipid-regulating statin therapy to prevent CAD events... - Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD)Vijay Nambi
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA
Platelets 20:199-205. 2009..Although the mechanism for these observed differences are not clear, we hypothesize that in vivo platelet activation in PAD patients may contribute to the differences and will need to be further investigated... - Matrix metalloproteinase-1 and tissue inhibitors do not predict incident coronary artery disease in the atherosclerosis risk in communities (ARIC) studyVijay Nambi
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Tex Heart Inst J 35:388-94. 2008.... - Intercellular Adhesion Molecule-1 G241R Polymorphism Predicts Risk of Incident Ischemic Stroke: Atherosclerosis Risk in Communities StudyKelly A Volcik
Human Genetics Center, University of Texas Houston Health Science Center, 1200 Herman Pressler Dr, Houston, TX 77030
Stroke 41:1038-40. 2010..05) and blacks (hazard rate ratio=7.04; 95% CI, 3.72 to 13.3; P<0.001). CONCLUSIONS: The intercellular adhesion molecule-1 241RR genotype is associated with an increased risk of incident ischemic stroke in both whites and blacks... - Role of non-high-density lipoprotein cholesterol in prevention of cardiovascular disease: updated evidence from clinical trialsAntonios M Xydakis
Division of Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
Curr Opin Cardiol 18:503-9. 2003..Statin therapy, which has already been demonstrated to decrease cardiovascular morbidity and mortality, provides significant reductions in non-high-density lipoprotein cholesterol... - Inflammatory protein levels and depression screening after coronary stenting predict major adverse coronary eventsLorraine Frazier
School of Nursing, Texas Heart Institute at St Luke s Episcopal Hospital, Houston, Texas 77030, USA
Biol Res Nurs 11:163-73. 2009..We examined levels of inflammatory proteins to be possible predictors of future MACE and physiological and psychological factors that initiate temporal increases in inflammatory protein levels... - Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patientsJoel D Morrisett
The Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
J Lipid Res 43:1170-80. 2002.... - How to identify patients with vulnerable plaquesSalim S Virani
Section of Cardiology, Baylor College of Medicine and Texas Heart Institute, St Luke s Episcopal Hospital, Houston, TX, USA
Diabetes Obes Metab 10:824-33. 2008.... - Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) studyKelly A Volcik
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, United States
Atherosclerosis 195:e76-82. 2007..We also tested common haplotypes in the PSEL and PSGL-1 genes to assess associations with incident CHD and ischemic stroke... - Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcriptionChu Huang Chen
MS A 601, Department of Medicine, Baylor College of Medicine, 6565 Fannin St, Houston, Texas 77030, USA
Circulation 107:2102-8. 2003..Apoptosis of vascular endothelial cells (ECs) can be induced in vitro by experimentally modified LDL. Description of proapoptotic circulating lipoproteins may significantly enhance understanding of atherothrombosis pathophysiology... - Relationship of alcohol consumption and type of alcoholic beverage consumed with plasma lipid levels: differences between Whites and African Americans of the ARIC studyKelly A Volcik
Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA
Ann Epidemiol 18:101-7. 2008..The influence of different types of alcoholic beverages on plasma lipid levels has been investigated to a lesser extent and in limited populations... - Extra domain A and type III connecting segment of fibronectin in assembly and cleavageYasunori Abe
Section of Atherosclerosis and Lipoprotein Research, Department of Medicine, Baylor College of Medicine, USA
Biochem Biophys Res Commun 338:1640-7. 2005.... - Lipoprotein-associated phospholipase A2: pathogenic mechanisms and clinical utility for predicting cardiovascular eventsVijay Nambi
Section of Cardiology, Baylor College of Medicine, 6550 Fannin, SM 677, Houston, TX 77030, USA
Curr Atheroscler Rep 8:374-81. 2006..Statin therapy has been shown to reduce Lp-PLA(2), and selective inhibitors of Lp-PLA(2) are under development. Additional research is needed to further determine the role of Lp-PLA(2) in atherogenesis and atherothrombotic events... - Comparison of the instructional efficacy of Internet-based CME with live interactive CME workshops: a randomized controlled trialMichael Fordis
Center for Collaborative and Interactive Technologies, Department of Pediatrics, Baylor College of Medicine, Houston, Tex 77030, USA
JAMA 294:1043-51. 2005.... - Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) studyVijay Nambi
Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA
J Am Coll Cardiol 55:1600-7. 2010..We evaluated whether carotid intima-media thickness (CIMT) and the presence or absence of plaque improved coronary heart disease (CHD) risk prediction when added to traditional risk factors (TRF)... - From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part IMorteza Naghavi
The Center for Vulnerable Plaque Research, University of Texas Houston, The Texas Heart Institute, and President Bush Center for Cardiovascular Health, Memorial Hermann Hospital, Houston, USA
Circulation 108:1664-72. 2003..We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients... - Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levelsMaja Barbalic
Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA
Hum Mol Genet 19:1863-72. 2010..These results provide new insights into adhesion molecule biology... - Endothelial lipase and cholesterol metabolismMehmet Cilingiroglu
Section of Cardiology and Atherosclerosis, Baylor College of Medicine, One Baylor Plaza, Jewish Building 519 D, Houston, TX 77030, USA
Curr Atheroscler Rep 6:126-30. 2004..The expression is highly regulated by cytokines and physical forces. These data suggest that EL may play a significant role in atherosclerosis... - Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities StudyJustin T Saunders
6565 Fannin, MS A 601, Houston, TX 77030, USA
Circulation 123:1367-76. 2011.... - Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndromeDonald B Hunninghake
Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA
Clin Ther 25:1670-86. 2003..However, although atorvastatin produced slightly larger decreases in TG, simvastatin produced larger increases in HDL-C... - Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities studyBruce B Duncan
Graduate Studies Program in Epidemiology, School of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil
Diabetes 52:1799-805. 2003..7 (P for linear trend = 0.008). In conclusion, a low-grade inflammation predicts incident type 2 diabetes. The association is absent in smokers and African-Americans... - Prevalence of metabolic syndrome and associated risk factors in Asian IndiansAjay Balasubramanyam
Emory University, Atlanta, GA, USA
J Immigr Minor Health 10:313-23. 2008..This study examined the association between metabolic syndrome, lifestyle behaviors, and perception and knowledge of current health and cardiovascular disease (CVD) among Asian Indians in the US... - Plasma lipid profile and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) studyEyal Shahar
Division of Epidemiology, University of Minnesota, 1300 South Second St, Suite 300, Minneapolis, MN 55454, USA
Stroke 34:623-31. 2003..The role of circulating lipids and lipoproteins in the pathogenesis of ischemic stroke remains uncertain despite 3 decades of research. We examined this issue in a large population-based cohort... - Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patientsAlberico L Catapano
University of Milan, Milan, Italy
Curr Med Res Opin 22:2041-53. 2006..To assess the lipid-altering efficacy and safety of ezetimibe/simvastatin single tablet product compared with rosuvastatin at the approved usual starting, next highest, and maximum doses... - Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial diseaseDennis W Schneck
AstraZeneca LP, Wilmington, Delaware 19850 5437, USA
Am J Cardiol 91:33-41. 2003..Significantly greater triglyceride decreases were seen at 80 mg with atorvastatin over rosuvastatin. Both rosuvastatin and atorvastatin were well tolerated over 6 weeks... - An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities studyAaron R Folsom
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN 55454 1015, USA
Arch Intern Med 166:1368-73. 2006..There has been interest in recent years in whether additional, and in particular novel, risk factors or blood markers, such as C-reactive protein, can enhance existing coronary heart disease (CHD) prediction models... - Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adultsJennifer A Nettleton
Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis 55454, USA
Atherosclerosis 194:e131-40. 2007..In conclusion, these data show that plasma HDL-C differs according to LIPC, LPL, and CETP genotypes. In the case of LIPC and LPL, data suggest dietary fat modifies these relations... - A prospective study of plasma ferritin level and incident diabetes: the Atherosclerosis Risk in Communities (ARIC) StudyMegan L Jehn
Department of Epidemiology, Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA
Am J Epidemiol 165:1047-54. 2007..Longitudinal studies with repeated measurements of glucose and iron metabolism parameters are needed to establish the role of iron stores and plasma ferritin in diabetes development...
Research Grants
- T Cells, Macrophages, Chemokines, and Adiposopathy in Diet-Induced ObesityChristie M Ballantyne; Fiscal Year: 2010..To test our hypothesis, we will study the effects of diet-induced obesity on a number of factors related to inflammation in mice and also in human fat cells. ..
- Obesity, Inflammation and Thrombosis: LOOK AHEADChristie Ballantyne; Fiscal Year: 2009....
- Obesity, Inflammation and Thrombosis: LOOK AHEADChristie Ballantyne; Fiscal Year: 2007....
- MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTIONChristie Ballantyne; Fiscal Year: 2002..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
- Obesity, Inflammation and Thrombosis: LOOK AHEADChristie M Ballantyne; Fiscal Year: 2010....